CGON — CG Oncology, Inc. catalysts
Next verified catalyst
2026-11-01 — A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIB · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11 (month) in 3mo
ESTIMATED |
READOUT
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate
Phase 3 · Non Muscle Invasive Bladder Cancer, Urologic Cancer |
CGON CG Oncology, Inc. | Cretostimogene Grenadenorepvec, n-dodecy |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|